The aim: The aim of this study was to investigate disease-free and overall survival in patients with stage IIII A NSCLC after neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy, and neoadjuvant chemotherapy. Materials and methods: For the study, 3 groups of 65 people were taken. All patients underwent radical surgery in the form of lobectomy, bilobectomy or pneumonectomy. All groups received 3 or 4 courses of neoadjuvant chemotherapy according to the scheme Docitaxel (Paclitaxel) and Cisplatin (Carboplatin), while groups II and III also received, respectively, neoadjuvant and adjuvant radiation therapy in the amount of 30 Gy to the chest and mediastinum. Survival was assessed using the Kaplan and Mayer scale. Results: 1. At a survival period of 6 months, the results of relapse-free survival in the NCRT and NCT groups do not differ. 2. From 12 months to 5 years, the highest recurrencefree survival rates are observed in the NHL group. 3. The overall five-year survival rate in the main group was 28.1±5.9%, in the NCT group - 10.4±3.8% and - 5.8±2.0% in the NCT + RT group. Conclusions: The best recurrence-free survival results are observed in the NHLT group. Also, the largest number of cases of molars morphological response, correlated with the highest survival rates, also occurs in the NHL group.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.